An open-label, Randomized, Single-dose, 2-Period, "-Treatment Crossover Study to Assess the Bioequivalence of Cinacalcet Capsule (Administered as Six of the 5 mg Cinacalcet Capsules) with 30 mg Commercial Tablet in Healthy Adult Volunteers.
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Cinacalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 15 Nov 2017 New trial record